NEW YORK (GenomeWeb News) – Investment bank Cowen & Co. today upgraded shares of Qiagen to Market Perform, citing the firm's recently acquired Ingenuity business, stabilization in its US human papillomavirus business, and Qiagen's movement toward higher growth businesses.

In addition to upgrading his rating for the company from Underperform, analyst Doug Schenkel raised the price target for its stock to $21 from $15.50, and increased his full-year 2013 EPS estimate to approximately $1.10 from $1.06.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.